Envista Holdings Corporation (NYSE:NVST – Get Free Report) has been given an average rating of “Moderate Buy” by the sixteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $27.0769.
A number of equities analysts have recently commented on the stock. Mizuho lifted their target price on shares of Envista from $24.00 to $27.00 and gave the company a “neutral” rating in a report on Tuesday, February 10th. William Blair upgraded shares of Envista from a “hold” rating to an “outperform” rating in a research note on Friday, February 6th. Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 26th. Robert W. Baird set a $30.00 price target on Envista in a research report on Friday, February 6th. Finally, UBS Group increased their price objective on Envista from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 3rd.
View Our Latest Stock Analysis on NVST
Insider Buying and Selling
Institutional Investors Weigh In On Envista
Several institutional investors have recently made changes to their positions in NVST. Royal Bank of Canada raised its stake in shares of Envista by 26.6% during the 1st quarter. Royal Bank of Canada now owns 23,240 shares of the company’s stock worth $401,000 after buying an additional 4,885 shares during the last quarter. Millennium Management LLC raised its position in Envista by 218.6% during the first quarter. Millennium Management LLC now owns 383,966 shares of the company’s stock worth $6,627,000 after acquiring an additional 263,442 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Envista by 39.3% during the first quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company’s stock worth $10,859,000 after acquiring an additional 177,630 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Envista by 15.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company’s stock valued at $9,821,000 after purchasing an additional 76,246 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its position in shares of Envista by 15.0% in the second quarter. Envestnet Asset Management Inc. now owns 230,759 shares of the company’s stock valued at $4,509,000 after purchasing an additional 30,051 shares during the last quarter.
Envista Stock Down 0.3%
NVST opened at $29.22 on Friday. Envista has a one year low of $14.22 and a one year high of $30.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.04 and a current ratio of 2.38. The stock has a market capitalization of $4.79 billion, a P/E ratio of 104.35, a price-to-earnings-growth ratio of 2.00 and a beta of 1.01. The business’s 50-day simple moving average is $25.17 and its 200-day simple moving average is $22.16.
Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.During the same quarter in the prior year, the firm posted $0.24 EPS. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Analysts anticipate that Envista will post 1 EPS for the current year.
Envista Company Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Read More
- Five stocks we like better than Envista
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon
- The Biggest IPO Ever… Open to Everyday Folks
- Silver records prices are great. Monthly income is better
- Read this or regret it forever
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
